Abstract

The most common liver disorder in developed countries is the Non-alcoholic fatty liver disease (NAFLD) [1,2]. Insulin resistance and the metabolic syndrome are both related to NAFLD [3]. The disease occurs up to 80% of obese people [4]. The most extreme form of NAFLD is Nonalcoholic steatohepatitis (NASH) which is the major cause of cirrhosis of the liver of unknown cause [5]. More commonly NAFLD is detected routine blood tests followed by diagnosed abnormal liver function tests. In the presence of insulin resistance and metabolic syndrome (obesity, combined hyperlipidemia, diabetes mellitus (type II), and high blood pressure ) NAFLD may seen often [3,5]. A spectrum of disease activity is being considered to cover in NAFLD. This spectrum begins as fatty accumulation in the liver (hepatic steatosis). A liver can remain fatty liver could work without any disturbing liver function, but by varying mechanisms and possible insults to the liver may also progress to become non-alcoholic steatohepatitis (NASH), a state in which steatosis is combined with inflammation and fibrosis (steatohepatitis). NASH is a progressive disease: over a 10-year period and also up to 20% of patients with NASH may develop cirrhosis of the liver, and 10% will suffer death related to liver disease [6].